Recurrent Squamous Cell Carcinoma of the Larynx Terminated Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0028811 (Recurrent Squamous Cell Carcinoma of the Larynx)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00906360Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTreatment